BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT
Delisted
BMY.RT was delisted on the 31st of December, 2020.
569 hedge funds and large institutions have $1.18B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 119 increasing their positions, 186 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
36% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 186
37% less capital invested
Capital invested by funds: $1.89B → $1.18B (-$705M)
Holders
569
Holding in Top 10
10
Calls
$15.5M
Puts
$560K
Top Buyers
| 1 | +$38M | |
| 2 | +$34.7M | |
| 3 | +$17.4M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$16M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$13.8M |
Top Sellers
| 1 | -$34.8M | |
| 2 | -$21.8M | |
| 3 | -$18.9M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$12.3M |